0
2020
Cephalosporin Market

Cephalosporin Market by Generation (First-generation, Second-generation, Third-Generation, Fourth-Generation, and Fifth-Generation), Type (Branded and Generic), Route of Drug Administration (Intravenous and Oral), and Application (Respiratory Tract Infection, Skin Infection, Ear Infection, Urinary Tract Infection, and Sexually Transmitted Infection): Global Opportunity Analysis and Industry Forecast, 2019–2027
Update Available On-Demand

A03170
Pages: 266
Oct 2020 | 20265 Views
Author(s) : Surabhi Pandey , Onkar Sumant
Tables: 154
Charts: 54
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cephalosporin Market

Request Now !

The global cephalosporin market size was valued at $13.69 billion in 2019, and is estimated to reach $16.87 Billion by 2027, growing at a CAGR of 2.6% from 2019 to 2027. 

Cephalosporin is a bactericidal, broad-spectrum, and β-lactam antibiotic originally derived from fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, gonorrhea, and others. They inhibit enzymes in cell wall of susceptible bacteria, disrupting cell synthesis. Cephalosporins are mainly designated for prophylaxis as well as treatment of infections caused by bacteria. First-generation cephalosporins are active mainly against gram-positive bacteria, such as Streptococcus and Staphylococcus. Hence, they are used primarily for soft tissue and skin infections as well as to prevent from hospital-acquired surgical infections. Successive generations i.e. from second-generation to fifth generation of cephalosporins have increased activity against gram-negative bacteria and gram-positive organisms. Cephalosporin may be used for patients who are allergic to penicillin due to different β-lactam antibiotic structure.

Cephalosporin-Market-2019-2027

Get more information on this report : Request Sample Pages

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 19 (COVID-19), a novel human coronavirus responsible for about 300,000 deaths worldwide. Till date, there is no confirmed treatment or vaccine prevention strategy against COVID-19. Hence, owing to urgent need for effective treatment, drug repurposing is regarded as the immediate option. Potential drugs can be identified via silico drug screening experiments. Thereby, in vitro and in vivo studies are going on to evaluate the potential of generations of cephalosporin for COVID-19.

The global cephalosporin market is experiencing growth, owing to surge in prevalence of infectious diseases, increase in R&D activities for development of combination drugs, and rise in funding for development of antibiotics. In addition, rise in demand for antibacterial drugs further drives growth of the global cephalosporin market. However, side effects associated with cephalosporin, uncertain regulatory reforms, antibiotic resistance to cephalosporin, and less drugs in pipeline are projected to impede the cephalosporin market growth. On the contrary, discovery of advanced prospect molecules and introduction of novel combination therapies to treat antibiotic-resistant microbial infections are expected to offer remunerative opportunities for the market players.

The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. On the basis of generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generic. Depending on route of administration, it is classified into intravenous and oral. Applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Cephalosporin Market
By Generation

Your browser does not support the canvas element.

Third-generation Cephalosporin holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Generation segment review

On the basis of generation, the third-generation cephalosporin segment generated the highest revenue in 2019, and is anticipated to maintain its dominance throughout the forecast period, as these are used for treatment of gram-negative bacillary meningitis, serious infections of enterobacteriaceae, otitis media, pyelonephritis, skin & soft tissue infections, Lyme disease, and gonorrhea. However, the fifth-generation cephalosporin segment is expected to register highest CAGR during the forecast period, as these drugs possess strong activity against aerobic gram-negative bacteria and exceptional activity against aerobic gram-positive bacteria.

Cephalosporin Market
By Type

Your browser does not support the canvas element.

Branded is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Type segment review

By type, the generic cephalosporin drugs segment is projected to exhibit highest growth during the forecast period, as these drugs are available at a much lower cost as compared to branded drugs. Moreover, pharmacological effects of generic drugs are exactly same as those of their brand-name counterparts.

Cephalosporin Market
By Region

2027
Asia-pacific 
North America
Europe
Lamea

Asia-Pacific would exhibit the highest CAGR of 3.6% during 2019-2027.

Get more information on this report : Request Sample Pages

Region segment review

Region wise, the antibiotics market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. Asia-Pacific dominated the market in 2019, accounting for the highest share, and is anticipated to maintain this trend throughout the forecast period. This is attributed to increase in consumption of cephalosporin, easier availability, and rise in demand for over-the-counter drugs, and increase in bacterial infection in the region.

The report provides a comprehensive analysis of the key players operating in the global cephalosporin industry, namely, Allergan Plc., Bristol-Myers Squibb Company, F.Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Lupin Limited (Lupin Pharmaceuticals, Inc.), Merck & Co. Inc., Novartis International AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. The other players in the value chain include Eli Lilly and Company, Bayer HealthCare, Sun Pharmaceutical, and Shionogi.

Key Benefits For Stakeholders

  • This report provides a detailed quantitative analysis of the current cephalosporin market trends and cephalosporin market forecast estimations from 2019 to 2027, which assists to identify the prevailing cephalosporin market opportunities. 
  • An in-depth cephalosporin market analysis includes analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global cephalosporin market is provided.
  • Region-wise and country-wise cephalosporin market conditions are comprehensively analyzed in this report.
  • The projections in this report are made by analyzing the current trends and future market potential from 2019 to 2027 in terms of value.
  • An extensive analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves.
  • Key market players within the cephalosporin market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of global cephalosporin market.

Key Market Segments

  • By Generation
    • First-generation Cephalosporin
    • Second-generation Cephalosporin
    • Third-generation Cephalosporin
    • Fourth-generation Cephalosporin
    • Fifth-generation Cephalosporin
  • By Type
    • Branded
    • Generic
  • By Route Of Administration
    • Intravenous
    • Oral
  • By Application
    • Respiratory Tract Infection
    • Skin Infection
    • Ear Infection
    • Urinary Tract Infection
    • Sexually Transmitted Infection
    • Others
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • India
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA


Key Market Players

  • ABBVIE INC. (ALLERGAN PLC.)
  • BRISTOL-MYERS SQUIBB COMPANY
  • F. HOFFMANN-LA ROCHE LTD.
  • GLAXOSMITHKLINE PLC
  • LUPIN LIMITED (LUPIN PHARMACEUTICALS, INC.)
  • MERCK & CO., INC.
  • NOVARTIS INTERNATIONAL AG (SANDOZ)
  • PFIZER INC.
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
 

Loading Table Of Content...


 
 

Rise in global prevalence of pneumonia, tonsillitis, bronchitis, and gonorrhea constitutes a major proportion of health and economic burden. Therefore, the adoption of cephalosporin is expected to increase in the near future. Moreover, increase in R&D activities for the development of combination drugs and rise in funding for the development of antibiotics further drives the market growth. Fifth-generation and fourth-generation of cephalosporin are expected to provide lucrative opportunities to market players, owing to the surge in prevalence of bacterial infectious diseases and increasing antimicrobial resistance.

Asia-Pacific is expected to grow at the highest CAGR during the study period. This is attributable to easy obtainability of cephalosporin over the counter and no obligation on their usage in this region. In addition, Asia-Pacific and LAMEA are expected to offer lucrative opportunities to the key players during the forecast period, due to high prevalence of infectious diseases and rise in demand for cephalosporin.


 

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

 Request Sample
 
FREQUENTLY ASKED QUESTIONS?

A. The market value of Global Cephalosporin market was $13.69 billion in 2019.

A. The forecast period is from 2019 to 2027.

A. The market value of Global Cephalosporin market in 2020 is $14.86 billion.

A. The Global Cephalosporin market is expected to exhibit significant growth during the forecast period, owing to surge in prevalence of infectious diseases, increase in R&D activities for development of combination drugs, and rise in funding for development of antibiotics

A. The base year is 2019 in Global Cephalosporin market

A. Based on generation, the third-generation cephalosporin segment held a major share in the Global Cephalosporin market in 2019 and is expected to continue the trend in the forecasting period.

RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Cephalosporin Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers